Jeffrey A. Cohen
Pathology and Forensic Medicine · 2008–2017
A researcher in the Science corpus: 7 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Pathology and Forensic Medicine — 49 citations into it
Whom Jeffrey A. Cohen trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- Lauren B. Krupp (in Pathology and Forensic Medicine)
Papers from Jeffrey A. Cohen's perspective
Ordered by how strongly the researchers Jeffrey A. Cohen trusts endorse each paper. Same corpus, a different order for every researcher.
- Revised diagnostic criteria for neuromyelitis optica (Neurology)
- A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. (The Lancet)
- Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis (Annals of Neurology)
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria (Annals of Neurology)
- Differential diagnosis of suspected multiple sclerosis: a consensus approach (Multiple Sclerosis)
- The spectrum of neuromyelitis optica. (Lancet Neurology)
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial (Annals of Neurology)
- Neuromyelitis optica and non organ-specific autoimmunity. (Archives of Neurology)
- Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. (Archives of Neurology)
- Fatigue in Multiple Sclerosis (CNS Drugs)
Their papers
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria (2011) — 9,812 citations
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. (2017) — 6,885 citations
- Defining the clinical course of multiple sclerosis (2014) — 2,587 citations
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. (2012) — 1,153 citations
- Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. (2010) — 2,166 citations
- Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls (2008) — 650 citations
- Differential diagnosis of suspected multiple sclerosis: a consensus approach (2008) — 659 citations